These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 28302150)

  • 1. Identification of a tripartite interaction between the N-terminus of HIV-1 Vif and CBFβ that is critical for Vif function.
    Desimmie BA; Smith JL; Matsuo H; Hu WS; Pathak VK
    Retrovirology; 2017 Mar; 14(1):19. PubMed ID: 28302150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dispersed and conserved hydrophobic residues of HIV-1 Vif are essential for CBFβ recruitment and A3G suppression.
    Zhou X; Han X; Zhao K; Du J; Evans SL; Wang H; Li P; Zheng W; Rui Y; Kang J; Yu XF
    J Virol; 2014 Mar; 88(5):2555-63. PubMed ID: 24352440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Core binding factor beta plays a critical role by facilitating the assembly of the Vif-cullin 5 E3 ubiquitin ligase.
    Fribourgh JL; Nguyen HC; Wolfe LS; Dewitt DC; Zhang W; Yu XF; Rhoades E; Xiong Y
    J Virol; 2014 Mar; 88(6):3309-19. PubMed ID: 24390320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vif-CBFβ interaction is essential for Vif-induced cell cycle arrest.
    Du J; Rui Y; Zheng W; Li P; Kang J; Zhao K; Sun T; Yu XF
    Biochem Biophys Res Commun; 2019 Apr; 511(4):910-915. PubMed ID: 30851937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of Vif-Mediated Degradation of APOBEC3G through Competitive Binding of Core-Binding Factor Beta.
    Miyagi E; Welbourn S; Sukegawa S; Fabryova H; Kao S; Strebel K
    J Virol; 2020 Mar; 94(7):. PubMed ID: 31941780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV type 1 viral infectivity factor and the RUNX transcription factors interact with core binding factor β on genetically distinct surfaces.
    Hultquist JF; McDougle RM; Anderson BD; Harris RS
    AIDS Res Hum Retroviruses; 2012 Dec; 28(12):1543-51. PubMed ID: 22725134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Core Binding Factor β Protects HIV, Type 1 Accessory Protein Viral Infectivity Factor from MDM2-mediated Degradation.
    Matsui Y; Shindo K; Nagata K; Yoshinaga N; Shirakawa K; Kobayashi M; Takaori-Kondo A
    J Biol Chem; 2016 Nov; 291(48):24892-24899. PubMed ID: 27758855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defining HIV-1 Vif residues that interact with CBFβ by site-directed mutagenesis.
    Matsui Y; Shindo K; Nagata K; Io K; Tada K; Iwai F; Kobayashi M; Kadowaki N; Harris RS; Takaori-Kondo A
    Virology; 2014 Jan; 449():82-7. PubMed ID: 24418540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel HIV-1 inhibitor that blocks viral replication and rescues APOBEC3s by interrupting vif/CBFβ interaction.
    Duan S; Wang S; Song Y; Gao N; Meng L; Gai Y; Zhang Y; Wang S; Wang C; Yu B; Wu J; Yu X
    J Biol Chem; 2020 Oct; 295(43):14592-14605. PubMed ID: 32817167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of the interaction of full-length HIV-1 Vif protein with its key regulator CBFβ and CRL5 E3 ubiquitin ligase components.
    Zhou X; Evans SL; Han X; Liu Y; Yu XF
    PLoS One; 2012; 7(3):e33495. PubMed ID: 22479405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Requirement of HIV-1 Vif C-terminus for Vif-CBF-β interaction and assembly of CUL5-containing E3 ligase.
    Wang H; Lv G; Zhou X; Li Z; Liu X; Yu XF; Zhang W
    BMC Microbiol; 2014 Nov; 14():290. PubMed ID: 25424878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dominant Negative Mutants of Human Immunodeficiency Virus Type 1 Viral Infectivity Factor (Vif) Disrupt Core-Binding Factor Beta-Vif Interaction.
    Duan S; Yu X; Wang C; Meng L; Gai Y; Zhou Y; Gu T; Yu B; Wu J; Yu X
    J Virol; 2022 Sep; 96(17):e0055522. PubMed ID: 35950859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design of Vif-Derived Peptide Inhibitors with Anti-HIV-1 Activity by Interrupting Vif-CBFβ Interaction.
    Gai Y; Duan S; Wang S; Liu K; Yu X; Yang C; Li G; Zhou Y; Yu B; Wu J; Wang C; Yu X
    Viruses; 2024 Mar; 16(4):. PubMed ID: 38675833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interactions between HIV-1 Vif and human ElonginB-ElonginC are important for CBF-β binding to Vif.
    Wang X; Wang X; Zhang H; Lv M; Zuo T; Wu H; Wang J; Liu D; Wang C; Zhang J; Li X; Wu J; Yu B; Kong W; Yu X
    Retrovirology; 2013 Aug; 10():94. PubMed ID: 23988114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a Conserved Interface of Human Immunodeficiency Virus Type 1 and Feline Immunodeficiency Virus Vifs with Cullin 5.
    Gu Q; Zhang Z; Gertzen CGW; Häussinger D; Gohlke H; Münk C
    J Virol; 2018 Mar; 92(6):. PubMed ID: 29263270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CBFβ enhances de novo protein biosynthesis of its binding partners HIV-1 Vif and RUNX1 and potentiates the Vif-induced degradation of APOBEC3G.
    Miyagi E; Kao S; Yedavalli V; Strebel K
    J Virol; 2014 May; 88(9):4839-52. PubMed ID: 24522927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F.
    Russell RA; Pathak VK
    J Virol; 2007 Aug; 81(15):8201-10. PubMed ID: 17522216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Core-binding factor β increases the affinity between human Cullin 5 and HIV-1 Vif within an E3 ligase complex.
    Salter JD; Lippa GM; Belashov IA; Wedekind JE
    Biochemistry; 2012 Nov; 51(44):8702-4. PubMed ID: 23098073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-1 and HIV-2 Vif interact with human APOBEC3 proteins using completely different determinants.
    Smith JL; Izumi T; Borbet TC; Hagedorn AN; Pathak VK
    J Virol; 2014 Sep; 88(17):9893-908. PubMed ID: 24942576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple lysines combined in HIV-1 Vif determines the responsiveness to CBF-β.
    Ai Y; Ma J
    Biochem Biophys Res Commun; 2015 Feb; 457(3):385-90. PubMed ID: 25582776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.